The findings of a disease-attenuating effect of IL17A in some, but not all, mouse models of colitis is also reflected in human studies that showed exacerbation of intestinal inflammation in IBD patients treated with IL17 targeting biologicals (31, 32). Here, IL17A is linked to inflammatory bowel disease.